Vascular Dementia May Not Be Distinct Clinical Entity, FDA Cmte. Says
Executive Summary
Vascular dementia may not be a distinct clinical entity that could be indicated in drug labeling, FDA's Peripheral & Central Nervous System Drugs Advisory Committee suggested.
You may also be interested in...
Andrx To Launch Lovastatin XL In 2002 With 150-Rep Sales Force
Andrx plans to launch extended-release lovastatin in 2002 for hyperlipidemia with three years of exclusivity, President Elliot Hahn, PhD, announced March 28 at the Banc of America Securities Healthcare Conference in Las Vegas.
Andrx To Launch Lovastatin XL In 2002 With 150-Rep Sales Force
Andrx plans to launch extended-release lovastatin in 2002 for hyperlipidemia with three years of exclusivity, President Elliot Hahn, PhD, announced March 28 at the Banc of America Securities Healthcare Conference in Las Vegas.
Janssen Reminyl Benefit Seen Among Probable Vascular Dementia Patients
A study of Janssen's Reminyl (galantamine) showed benefits in patients with probable vascular dementia as well as patients with Alzheimer's disease with cerebrovascular components.